Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib

C. Serrano, S. Bauer, D. Gómez-Peregrina, Y. K. Kang, R. L. Jones, P. Rutkowski, O. Mir, M. C. Heinrich, W. D. Tap, K. Newberry, A. Grassian, H. Shi, S. Bialick, P. Schöffski, M. A. Pantaleo, M. von Mehren, J. C. Trent, S. George

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Background: The current treatment paradigm of imatinib-resistant metastatic gastrointestinal stromal tumor (GIST) does not incorporate KIT/PDGFRA genotypes in therapeutic drug sequencing, except for PDGFRA exon 18-mutant GIST that is indicated for avapritinib treatment. Here, circulating tumor DNA (ctDNA) sequencing was used to analyze plasma samples prospectively collected in the phase III VOYAGER trial to understand how the KIT/PDGFRA mutational landscape contributes to tyrosine kinase inhibitor (TKI) resistance and to determine its clinical validity and utility. Patients and methods: VOYAGER (N = 476) compared avapritinib with regorafenib in patients with KIT/PDGFRA-mutant GIST previously treated with imatinib and one or two additional TKIs (NCT03465722). KIT/PDGFRA ctDNA mutation profiling of plasma samples at baseline and end of treatment was assessed with 74-gene Guardant360® CDx. Molecular subgroups were determined and correlated with outcomes. Results: A total of 386/476 patients with KIT/PDGFRA-mutant tumors underwent baseline (pre-trial treatment) ctDNA analysis; 196 received avapritinib and 190 received regorafenib. KIT and PDGFRA mutations were detected in 75.1% and 5.4%, respectively. KIT resistance mutations were found in the activation loop (A-loop; 80.4%) and ATP-binding pocket (ATP-BP; 40.8%); 23.4% had both. An average of 2.6 KIT mutations were detected per patient; 17.2% showed 4-14 different KIT resistance mutations. Of all pathogenic KIT variants, 28.0% were novel, including alterations in exons/codons previously unreported. PDGFRA mutations showed similar patterns. ctDNA-detected KIT ATP-BP mutations negatively prognosticated avapritinib activity, with a median progression-free survival (mPFS) of 1.9 versus 5.6 months for regorafenib. mPFS for regorafenib did not vary regardless of the presence or absence of ATP-BP/A-loop mutants and was greater than mPFS with avapritinib in this population. Secondary KIT ATP-BP pocket mutation variants, particularly V654A, were enriched upon disease progression with avapritinib. Conclusions: ctDNA sequencing efficiently detects KIT/PDGFRA mutations and prognosticates outcomes in patients with TKI-resistant GIST treated with avapritinib. ctDNA analysis can be used to monitor disease progression and provide more personalized treatment.

Original languageEnglish
Pages (from-to)615-625
Number of pages11
JournalAnnals of Oncology
Volume34
Issue number7
DOIs
StatePublished - Jul 2023

Keywords

  • Adenosine Triphosphate/therapeutic use
  • Antineoplastic Agents/therapeutic use
  • Circulating Tumor DNA/genetics
  • Disease Progression
  • Gastrointestinal Stromal Tumors/drug therapy
  • Humans
  • Imatinib Mesylate
  • Mutation
  • Protein Kinase Inhibitors/therapeutic use
  • Proto-Oncogene Proteins c-kit/genetics
  • Receptor Protein-Tyrosine Kinases/genetics
  • Receptor, Platelet-Derived Growth Factor alpha/genetics

Fingerprint

Dive into the research topics of 'Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib'. Together they form a unique fingerprint.

Cite this